Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma 6Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Burkitt Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Pancreatic Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Advanced Solid Tumors 2Advanced Nonhematologic Malignancies 2Advanced Malignancies 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroblastoma 1

Interventions

Cyclophosphamide 61Rituximab 60Etoposide 28fludarabine phosphate 23Prednisone 23fludarabine 22Vincristine 19Filgrastim 19Doxorubicin 19ibrutinib 16Peripheral Blood Stem Cell Transplantation 16venetoclax 15Lenalidomide 14Bortezomib 14Carboplatin 13CT-P10 13Gemcitabine 12Vorinostat 11Cytarabine 11pembrolizumab 9Radiotherapy 9Melphalan 9Magnetic Resonance Spectroscopy 9Dexamethasone 9Bendamustine Hydrochloride 9Paclitaxel 8Ifosfamide 8Cyclosporine 8Biopsy 8Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large B-Cell, Diffuse × MLN 8237 × Clear all
NCT00697346 2019-05-31

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Takeda

Phase 1 Completed
58 enrolled 52 charts
LymphoidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Enteropathy-Associated T-Cell Lymphoma

NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02700022 2017-11-20

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

UNC Lineberger Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡